Indications -- Stroke Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Indications -- Stroke

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: nigel bates	2/22/2007 5:50:10 AM
	of 70

Ark wins key patent case on stroke in Europe London, UK 22 February 2007 - Ark Therapeutics Group plc ('Ark' or the 'Company') announces that following a hearing at the European Patent Office (EPO) it has been informed by its patent attorneys, Gill Jennings & Every LLP, that it has been successful in prosecuting Ark's patent application relating to its intellectual property concerning the use of agents that affect the angiotensin-renin system for the prevention and treatment of stroke. The patent will cover 23 molecules belonging to the therapeutic classes of angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor (ATII) blockers, many of which are already marketed for various indications. The geographic scope of the patent comprises the 18 European countries that belonged to the European Patent Convention in 1998. The European patent will give protection in the applicable European countries until 2018. Separate patent applications are under prosecution in the USA as well as in other international territories. In April 2005, Ark signed a licence agreement with Boehringer Ingelheim granting rights to Ark's intellectual property for the use of its products affecting the renin-angiotensin system. The deal comprised upfront and milestone payments and undisclosed royalties on sales of Boehringer Ingelheim's products for the indication of stroke in all territories in which Ark has secured patent protection. Formal grant of this European patent will trigger a milestone payment from Boehringer Ingelheim to Ark. Further financial details have not been disclosed. Dr Nigel Parker, CEO of Ark, commented: 'We are very pleased to announce this important patent news. The mitochondrial2 science on which the patent is based was an exciting very early discovery by Ark scientists and we are pleased to see the novelty being recognised by the European Patent Office in this third therapeutic application. Ark will now start to consider the further commercial licensing potential of the patent.'

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next